ARS Pharmaceuticals

Historical price data

ARS Pharmaceuticals is on a mission to transform the treatment of severe allergic reactions by developing needle-free, patient-friendly therapies. Its transformative achievement is the 2024 FDA approval of neffy®, the first needle-free epinephrine nasal spray, which directly tackles the underutilization of epinephrine due to fear, complexity, and portability issues with auto-injectors. The company's strategy is to commercialize neffy® in the substantial anaphylaxis market while advancing its intranasal platform into adjacent Type I hypersensitivity indications like urticaria, aiming to capture significant market share from entrenched auto-injector competitors.

Proprietary intranasal delivery platform engineered to deliver therapeutic doses of epinephrine through the nasal mucosa, utilizing absorption enhancers to achieve rapid systemic pharmacokinetics comparable to intramuscular injection.

ARS Pharma's direct competition consists of established epinephrine auto-injector brands (EpiPen, Auvi-Q, generics). Its competitive advantage is its first-mover status in the needle-free category, competing on usability and patient preference rather than price alone. In its pipeline urticaria indication, it faces less direct competition, targeting an unmet need for acute rescue therapy alongside chronic control agents.